Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study

BACKGROUND: Combining an antiangiogenic agent with an anti-PD-1 agent is a promising strategy for unresectable hepatocellular carcinoma (HCC). AIMS: To explore the effectiveness and tolerability of lenvatinib plus camrelizumab vs. lenvatinib monotherapy as a first-line treatment for unresectable HCC...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Qi, Cao, Mengran, Yuan, Guosheng, Cheng, Xiao, Zang, Mengya, Chen, Ming, Hu, Xiaoyun, Huang, Jing, Li, Rong, Guo, Yabing, Ruan, Jian, Chen, Jinzhang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8907842/
https://www.ncbi.nlm.nih.gov/pubmed/35280760
http://dx.doi.org/10.3389/fonc.2022.809709

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8907842/
https://www.ncbi.nlm.nih.gov/pubmed/35280760
http://dx.doi.org/10.3389/fonc.2022.809709

Ejemplares similares